Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 780-787

  Di Martino, Maria Teresa ^a   Arbitrio, Mariamena ^b   Leone, Emanuela ^a   Guzzi, Pietro Hiram ^a   Rotundo, Maria Saveria ^a   Ciliberto, Domenico ^a   Tomaino, Vera ^a   Fabiani, Fernanda ^a   Talarico, Danilo ^a   Sperlongano, Pasquale ^c   Doldo, Patrizia ^a   Cannataro, Mario ^a   Caraglia, Michele ^c   Tassone, Pierfrancesco ^a,d   Tagliaferri, Pierosandro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Temple University   (United States)

Author keywords

ABCC5; ABCG1; Colorectal cancer; DMET; Irinotecan; OATP1B1 SLCO1B1; Pharmacogenomics; Polymorphism; SNP; Toxicity

Indexed keywords

DRUG METABOLIZING ENZYME; IRINOTECAN;

ABCC5 GENE; ABCG1 GENE; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENE MAPPING; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MICROARRAY ANALYSIS; NEUTROPENIA; OATP1B1 GENE; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80655141268     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17781     Document Type: Article

References (44)

1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7; PMID:10744089; DOI:10.1016/S0140-6736(00)02034- 1.
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14; PMID:11006366; DOI:10.1056/NEJM200009283431302.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; DOI:10.1056/NEJMoa032691.
4. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34:656-69; PMID:18558463; DOI:10.1016/j.ctrv.2008.05.002.
5. Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20:81-7; PMID:11773157; DOI:10.1200/JCO.20. 1.81.
6. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004; 10:4068-71; PMID:15217940; DOI:10.1158/1078-0432.CCR-03-0591.
7. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-8; PMID:15007088; DOI:10.1200/JCO.2004.07.173.
8. Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration- resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010; 10:191-9; PMID:20038957; DOI:10.1038/tpj.2009.57.
9. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106-12; PMID:18250228; DOI:10.1182/blood-2007-11-122010.
10. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10:261-6; PMID:19207028; DOI:10.2217/14622416.10.2.261.
11. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol 2011; 154:529-33; PMID:21517810; DOI:10.1111/j.1365-2141.2011.08622.x.
12. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604-14; PMID:19349540; DOI:10.1200/JCO.2008.20.6300.
13. Fogli S, Caraglia M. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opin Pharmacother 2009; 10:1095-108; PMID:19405786; DOI:10.1517/14656560902889775.
14. Rabbee N, Speed TP. A genotype calling algorithmfor affymetrix SNP arrays. Bioinformatics 2006; 22:7- 12; PMID:16267090; DOI:10.1093/ bioinformatics/bti741.
15. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008; 14:1788-96; PMID:18347181; DOI:10.1158/1078-0432.CCR-07-1472.
16. Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009; 27:2419-21; PMID:19364959; DOI:10.1200/JCO.2008.20. 9478.
17. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226-36; PMID:15709193.
18. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, et al. Predictive role of the UGT1A1, UGT1A7 and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin and irinotecan. J Clin Oncol 2009; 27:2457-65; PMID:19364970; DOI:10.1200/JCO.2008.19.0314.
19. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006; 234:90-106; PMID:16343744; DOI:10.1016/j.canlet.2005.04.040.
20. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15:295-301; PMID:15864130; DOI:10.1097/01213011-200505000-00004.
21. Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 2007; 60:515-22; PMID:17406868; DOI:10.1007/s00280- 006-0396-1.
22. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76:528-35; PMID:15592324; DOI:10.1016/j.clpt.2004.08.007.
23. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6:71-84; PMID:12729805; DOI:10.1016/S1368-7646(03)00005-0.
24. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71:537-92; PMID:12045106; DOI:10.1146/annurev.biochem.71. 102301.093055.
25. Szakács G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13:379-93; PMID:18468555; DOI:10.1016/j.drudis.2007.12.010.
26. de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81:42-9; PMID:17185998; DOI:10.1038/sj.clpt.6100019.
27. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33:434-9; PMID:15608127; DOI:10.1124/dmd.104.001909.
28. Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006; 16:683-91; PMID:16906022; DOI:10.1097/01.fpc.0000230420.05221.71.
29. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan- pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008; 59:69-75; PMID:17766002; DOI:10.1016/j.lungcan.2007.07.019.
30. Tarr PT, Tarling EJ, Bojanic DD, Edwards PA, Baldan A. Emerging new paradigms for ABCG transporters. Biochim Biophys Acta 2009; 1791:584-93; PMID:19416657.
31. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005; 33:219-24; PMID:15523049; DOI:10.1124/dmd.104.001354.
32. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275:30069-74; PMID:10893247; DOI:10.1074/jbc.M005463200.
33. Kim SN, Ahn YH, Kim SG, Park SD, Cho-Chung YS, Hong SH. 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int J Cancer 2001; 93:33-41; PMID:11391618; DOI:10.1002/ijc.1308.
34. Tortora G, Tagliaferri P, Clair T, Colamonici O, Neckers LM, Robins RK, et al. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic and acute lymphocytic human leukemia cell lines. Blood 1988; 71:230-3; PMID:2825845.
35. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATPbinding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006; 99:9-17; PMID:16752223; DOI:10.1007/s10549-006- 9175-2.
36. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1:121-31; PMID:16054053; DOI:10.1016/j.cmet.2005.01.002.
37. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch- Ozcurumez M, Liebisch G, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 2000; 97:817-22; PMID:10639163; DOI:10.1073/pnas.97.2.817.
38. Wojcik AJ, Skaflen MD, Srinivasan S, Hedrick CC. A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol 2008; 180:4273-82; PMID:18322240.
39. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, et al. Carriers of lossof- function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010; 33:869-74; PMID:20067955; DOI:10.2337/dc09-1562.
40. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211:361-70; PMID:20138281; DOI:10.1016/j.atherosclerosis.2010.01.011.
41. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 2005; 15:303-9; PMID:15864131; DOI:10.1097/01213011-200505000-00005.
42. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234:4-33; PMID:16504381; DOI:10.1016/j. canlet.2005.06.051.
43. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 2007; 8:293-305; PMID:17324118; DOI:10.2217/14622416.8.3.293.
44. Hardenbol P, Baner J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21:673-8; PMID:12730666; DOI:10.1038/nbt821.